Background: Trials of renal denervation report drops of B30 mm Hg in office systolic blood pressure, yet reductions in ambulatory pressures appear to be B3-fold smaller. It has been claimed this disparity is seen in antihypertensive drug trials. We examine this office-ambulatory discrepancy though meta-analysis of drug trials reporting office and ambulatory pressures.
Introduction: Visit-to-visit systolic blood pressure variability (SBPV) is an independent risk factor for mortality and cardiovascular (CV) events in the general population. Studies in haemodialysis (HD) populations are confounded by inclusion of prevalent patients. We investigated the effects of SBPV on all-cause mortality in incident HD patients. Methods: We performed a longitudinal observational study of patients commencing HD between 2005 and 2011 in our region. We excluded patients with CV events within 6 months of starting HD. The exposure was SBPV assessed by standard deviation, coefficient of variation and variation independent of the mean (VIM) using short-gap, pre-dialysis SBP readings between 3-6 months after commencing HD. Results: 203 patients were included aged 66 ± 15 years, 66% male, 33% with previous CV disease, BP 144±16/75±10 mm Hg taking a mean of 2.0±1.3 antihypertensives. 37(18.2%) patients died during a follow-up of 2.0 ± 1.3 years. The HR for mortality adjusted for diabetes, CV disease, SBP and DBP was 1.09 (95%CI 1.02-1.16) for a one-unit increase of VIM. Those with VIM of SBP above the median were 2.4 (95%CI 1.17-4.74) times more likely to die during follow-up than those below the median (Fig.  1 ). Findings were similar for all measures of SBPV. Further adjustment for type of dialysis access, use of antihypertensives and mean intradialytic weight change did not alter these findings. Discussion: Variability of SBP is a strong and independent predictor of all-cause mortality in incident HD patients. Further research is needed to understand the mechanism as this may form a therapeutic target or focus for management.
2A.3. MRI is a safe and effective imaging strategy in the investigation of resistant hypertension
Burchell AE 1, 3 Background: In patients with early onset or drug resistant hypertension (HTN) exclusion of secondary causes with imaging and endocrine testing is recommended. Magnetic resonance imaging (MRI) is non-invasive, non-ionising and is the gold standard imaging modality for the quantification of cardiac volumes and masses. We proposed that a single MRI visit could provide all the imaging required in routine evaluation of patients with HTN.
Methods: Patients attending a specialist hypertension clinic with early onset (o40 years), drug resistant or challenging drug intolerant HTN underwent a Hypertension Protocol MRI scan assessing for end organ damage and secondary causes. This included imaging of the renal arteries, adrenals, aorta and heart as well as cerebral vessels. Data presented as mean ± s.e.m. Results: 56 patients (29 male), aged 54±2 years, had an office blood pressure of 179 ± 4/101 ± 2 mm Hg on 3.9 ± 0.3 antihypertensive medications. We identified 1 hypertrophic cardiomyopathy, 1 multinodular goitre, 2 renal artery stenoses, 4 adrenal masses and 3 cerebral microaneurysms. 15% had X1 accessory renal artery and 31% had X1 hypoplastic vertebral artery. 75% of patients had Abstracts left ventricular hypertrophy by left ventricular mass index (95.8±3.7 g/m 2 ). Conclusion: MRI is a safe and effective method of screening for secondary causes of HTN and could replace the combination of echocardiography, renal ultrasound and CT imaging. It also provides additional information for patients being considered for renal denervation and is likely to be a cost effective first line investigation for patients with possible secondary causes of hypertension.
2A.4. Relationship between air pollutants and blood pressure control and survival following hypertension diagnosis Robinson S, Hastie CE, Gilmore R, Dawson J, Muir S, Dominiczak AF, Touyz R and Padmanabhan S University of Glasgow, Glasgow, United Kingdom
Objective: There is evidence that air pollution, in the form of particulate matter (PM 2.5 and PM 10 ), nitrogen oxides (NO X ), sulphur dioxide (SO 2 ), and carbon dioxide (CO 2 ) is associated with blood pressure and in some cases mortality. We investigated the effect of these and other components of air pollution on blood pressure change and mortality. Methods: We studied 6040 patients attending the Glasgow Blood Pressure Clinic (GBPC) between 1990 and 2011, with 21 year follow-up for mortality outcomes. Geocoding using patient postcode enabled mapping of each subject to 25 air pollutants. Cox proportional hazards models were used to explore the multivariate-adjusted associations between individual pollutants and cause-specific mortality. Generalised estimating equations were used to estimate the effect of individual pollutants on follow-up systolic blood pressure (SBP).
Results: Over 21 years of follow up there were 670 deaths, of which 324 had a cardiovascular (CV) cause. PM 2.5 and PM 10 were significantly associated with all-cause, CV, and non-CV mortality risk (Po0.001, Po0.001, and Po0.05, respectively), and with SBP change over time (Po0.05). Eight other pollutants (butadiene, benzene, carbon monoxide, CO 2 , copper, NO X , selenium, and vanadium) were highly correlated (coefficient 40.80) with PM 2.5 and PM 10 . Two independent, i.e. not correlated with any others, pollutants (dioxins and volatile organic compounds) were also significantly associated with increasing SBP and mortality outcomes. Conclusions: Our data indicate that there are components of air pollution other than those previously reported that contribute to the progression of blood pressure and mortality outcomes.
2A.5. Maybe it's time for something a little different? The extent to which current pharmacotherapy practice conforms to national guidelines for primary for cardiovascular disease prevention Sheppard Figure) and multivariate (HR for Q3 Vs Q1: 0.41;95% CI:0.19-0.86) analyses. LVWT was not associated with mortality (log-rank P ¼ 0.7). Conclusions: Left ventricular pre-ejection wall stress is an independent risk factor for all-cause mortality in treated hypertension patients and has clinical implications.
3A.5. Microvascular autoregulatory response to ischaemia in the skin and association with mean blood oxygen saturation Adingupu DD, Thorn C, Casanova F, Elyas S, Gates PE, Strain WD and Shore AC Diabetes and Vascular Medicine, University of Exeter Medical School, Exeter, United Kingdom Introduction: We have previously described three distinct cutaneous microvascular responses to an ischaemic stimulus using laser Doppler fluximetry. These are associated with a gradation of cardiovascular risk. 1) 'normal response' with a controlled graded rise to peak at B10-15 s, 2) 'non-dominant early peak (NDEP),' with an abnormal early peak within 2 s of lower amplitude than the subsequent 'normal' graded rise to peak, 3) 'dominant early peak (DEP)' within 2 s of cuff release with maximum amplitude, which declines rapidly and is then followed by a lesser 'normal' peak. Exact mechanism involved in abnormal peak responses is unclear. Aims: To explore associations between microvascular autoregulatory responses and cutaneous blood oxygenation (SO 2 , %).
Methods: Post occlusive reactive hyperaemia of the microcirculation was assessed on the foot of participants with cardiovascular disease (CVD), diabetes (DM), both (DM þ CVD) or neither (controls) using laser Doppler fluximetry and Oxygen to See, which measures blood oxygen saturation in the first 1 mm of skin. All participants underwent basic demographic & biochemical screening. Results: 232 participants were studied, 76 controls, 106 with CVD, 34 with DM and 16 with DM þ CVD. Results were stratified by peak response groups. In keeping with previous reports, there was an increase in CVD, diabetes and CVD risk factors across peak response groups. Area under the curve of oxygen saturation was incrementally lower in those with impaired autoregulation. After adjustment for CVD, diabetes, blood pressure, heart rate and BMI, this remained strongly negatively associated with abnormal peak responses, geometric mean (95% CI) normal 1459(1364-1554) vs. NDEP 1212(1132-1292) (P ¼ 0.001) vs. DEP 1142(1040-1245) (Po0.001).
Conclusion: These data suggest that the previously described abnormal peak responses have significant consequences in the delivery of oxygen as they are independently associated with reduced mean oxygen saturation post ischaemia.
3A.6. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a meta-analysis Floyd CN, Ferro A King's College London, London, United Kingdom Introduction: The PlA1/A2 polymorphism of glycoprotein IIIa (GPIIIa) has been associated with both antiplatelet drug resistance and increased cardiovascular events. Here we present the first metaanalysis examining the impact of carriage of the PlA2 allele on the efficacy of the antiplatelet drugs aspirin and clopidogrel. Methods: Electronic databases (MEDLINE and EM-BASE) were searched for all articles evaluating genetic polymorphisms of GPIIIa. For studies where antiplatelet resistance was measured using validated techniques, pooled odds ratios (ORs) were calculated using fixed-effect and random-effect models. Results: 16 studies were eligible for statistical analysis and included 1650 PlA1 homozygous subjects and 668 carriers of the PlA2 allele. For carriers of the PlA2 allele, OR 0.924 (n ¼ 2318; 95% CI 0.743-1.151; P ¼ 0.481) was observed for resistance to either drug, OR 0.862 (n ¼ 2085; 95% CI 0.685-1.086; P ¼ 0.208) for resistance to aspirin and OR 1.429 (n ¼ 233; 95% CI 0.791-2.582; P ¼ 0.237) for resistance to clopidogrel. In the aspirin cohort, sub-group analysis revealed no statistical association in either healthy subjects or those with cardiovascular disease. PlA2 carriage was marginally associated with aspirin sensitivity using the fixed-effect model when identified by the PFA-100 assay (n ¼ 1151; OR 0.743, 95% CI 0.558-0.989; P ¼ 0.041) but with significant heterogeneity (I 2 ¼ 55%; P ¼ 0.002); significance was lost with analysis using a random-effect model.
Conclusions:
The totality of published data does not support an association between carriage of the PlA2 allele and antiplatelet drug resistance. Significant heterogeneity indicates the need for larger studies using validated assays.
3B.1. Allied health professional-led interventions for improving control of blood pressure in patients with hypertension: systematic review and meta-analysis Background: Nurse or pharmacist led care are promising methods of improving control of hypertension. We present findings from our current Cochrane review (A115), addressing the evidence for allied health professional led interventions in the management of hypertension. Methods: We searched multiple bibliographic databases to November 2011 for randomised controlled trials. We included any nursing, pharmacist, or allied health professional-led intervention designed to improve control of blood pressure (BP), compared to usual care in hypertension. Primary outcome measures were systolic and diastolic BP, and achievement of study target BP. Two authors independently identified eligible studies and assessed study quality using Cochrane criteria. Intervention effects were pooled using odds ratios (OR) or weighted mean differences (WMD). 
3B.3. Systolic arterial blood flow is underestimated by auscultation compared with doppler return-to-flow
Hussain S, Ali A, Glassey E and Lewis PS University of Manchester, Manchester, United Kingdom Introduction: Systolic blood pressure (SBP) is a key indicator of cardiovascular risk. It is therefore important to measure blood pressure accurately to aid diagnosis and research. Methods: We studied 24 females and 32 males aged between 18-85 years. With subjects in a sitting position with their left arm supported horizontal at level of shoulder, an A and D Medical UA 767 PC semi-automated blood pressure monitor was used to inflate and deflate an appropriately sized cuff placed on the upper arm. Three readings were taken at 1 min intervals. SBP was assessed, during cuff deflation, by simultaneous auscultation of first Korotkoff sound (K1) heard over brachial artery with the bell of a Littmann stethoscope and by the point of return of arterial blood flow measured by flat-bed Doppler probes placed over the brachial and radial arteries. Results: SBP measurements differed significantly between methods. The pressure at which arterial blood flow returned at the brachial Doppler was 5.58 mm Hg higher than K1 (95% CI 1.85 to 9.32, P value ¼ 0.004). The point of return of radial Doppler flow was 2.44 mm Hg higher than K1 (95% CI 0.66 to 4.21, P value ¼ 0.008). Conclusion: The traditional auscultatory method of blood pressure measurement underestimates systolic blood pressure compared with Doppler return-toflow whether measured at the brachial or radial arteries, leading to potential errors in assessing cardiovascular risk. Results: E90% of reads were mapped to the BN reference genome for SHRSP at 27 Â and WKY at 26 Â coverage. Genomic difference distribution of 1 163 332 single nucleotide polymorphisms and 213 130 insertions or deletions of DNA segments between SHRSP and WKY were not uniform. There were 769 non-synonymous coding, 5 stop gained, 24 frame shift coding variants within the congenic regions and significantly differently expressed genes were prioritised. This identified Gstm1, a previously validated positional and functional candidate for hypertension in SHRSP. Furthermore, Gstm7, Ampd2, Atp11b, Pik3r1 were positional candidate genes identified in the cluster analysis of Gstm1's. Conclusion: The integration of sequence variants and gene expression data has implicated and prioritised positional candidate genes that may contribute to blood pressure regulation and cardiac mass in the SHRSP.
4A.4. Ischemic preconditioning promotes intrinsic vascularisation and enhances growth of cardiac tissue Lim SY

Shiang Y Lim, Victoria, Australia
Objective: Ischemic preconditioning (IPC) is a powerful endogenous protective mechanism which involves release of paracrine factors that promote cell survival and angiogenesis. We aim to determine whether in vivo IPC might promote the growth and development of cardiac tissue in an in vivo tissue engineering setting. Methods: We employed a vascularized tissue engineering strategy where polyacrylic chambers were placed subcutaneously in the groin, enclosing the femoral vessels. IPC was induced by 3 cycles of 5 min femoral artery occlusion interspersed with 5 min reperfusion. Results: When chambers were implanted they filled with new vascularized tissue formed by outgrowth from the femoral vessels. Rats subjected to IPC generated bigger tissue constructs at 7 and 28 days (B50% increased in weight and volume vs. control, Po0.05) with higher microcirculatory vascular volume (B100% increased in lectin-positive blood vessels, Po0.05). To investigate the cytoprotective effect of IPC, neonatal rat cardiomyocytes (rCM) were implanted with fibrin gel into chambers. IPC significantly reduced apoptosis of rCM at 3 days post-implantation (B50% reduction in TUNEL positive and cleaved caspase-3 positive cells, Po0.05). At 28 days post-implantation, tissue constructs contracted spontaneously and IPC significantly increased the cardiac muscle volume, which was correlated with increased vascular volume.
Conclusion:
In vivo IPC promotes survival of implanted cardiomyocytes and is associated with enhanced angiogenesis. As neither genetic modification nor exogenous substances were required to achieve this beneficial effect, IPC may represent a new clinically adaptable approach to optimize tissue engineering of heart and other tissues with implanted cells.
8.1. The inter-arm blood pressure difference in people with diabetes: measurement, vascular, and mortality implications Clark CE, Steele AM, Taylor RS, Shore AC, Ukoumunne OC and Campbell JL University of Exeter Medical School, Exeter, United Kingdom Background: Differences in blood pressure between arms are associated with vascular disease and increased mortality in cohorts at elevated cardiovascular risk. The implications of an inter-arm difference (IAD) in diabetes, also a condition with increased cardiovascular risk, have not been reported. Uncertainty exists concerning how best to initially check for an IAD. We assessed a pragmatic measurement technique against gold standard in a community cohort with and without diabetes, and explored vascular associations of an IAD in diabetes. Methods: People with diabetes and spouse-controls recruited to the Diabetes Alliance for Research in England (DARE) had repeated brachial blood pressures measured simultaneously at recruitment. Mean IADs were examined for prospective mortality differences and cross-sectional associations. The data were used to inform a pragmatic measurement strategy.
Results: 8.6% of 514 participants with diabetes and 2.9% of 238 controls had a systolic IAD X10 mm Hg. Single pairs of blood pressure measurements had high negative predictive values (0.97 to 0.99) for excluding an IAD. In diabetes systolic IADs were associated with diabetic retinopathy (X10 mm Hg and X15 mm Hg), peripheral arterial disease (X10 mm Hg), and chronic kidney disease (X15 mm Hg) at recruitment. After 41 months systolic IADs were associated with increased cardiovascular mortality (hazard ratios 4.6 (1.2 to 17.6) for X10 mm Hg and 10.9 (2.3 to 51.3) for X15 mm Hg). Conclusions: Systolic IADs can be excluded on a single pair of measurements. In diabetes preliminary findings suggest that systolic IADs are associated with increased risk of mortality. Blood pressure should be measured in both arms during initial assessment in diabetes. Background: Renal denervation (RDN) is a promising therapy for resistant hypertension and has been shown to be effective in clinical trials. The role of RDN in routine clinical practice is less well established. We studied outcomes of pilot studies of RDN in two large tertiary referral centres for hypertension in the United Kingdom. Methods: Patients with office blood pressure (BP) X160/90 mm Hg on X3 antihypertensive agents and no secondary cause for hypertension were considered eligible for RDN. All patients underwent ambulatory blood pressure monitoring (ABPM) prior to and six months after RDN. Baseline and follow up medication and laboratory data were analysed. Results: 20 consecutive patients were studied (45% male, mean age 50.1 years). At baseline the mean clinic BP was 189/110 mm Hg with ABPM of 172/ 100 mm Hg. The median number of antihypertensive agents was 6 (range 4-8) At baseline therapy all patients received either angiotensin converting enzyme inhibitor or angiotensin receptor blocker, calcium channel blocker in 95% and diuretic in 90%. A wide range of renal function was studied (median creatinine 74 mmol/l, range 57-246). At six months following RDN, there was a significant fall in clinic systolic BP of 18 mm Hg (Po0.05) and systolic BP at ABPM of 9 mm Hg (Po0.05). There was a reduction in number of antihypertensives prescribed (median 4, Po0.01). There were no significant changes in renal function. 5 patients required extended hospital stay for symptomatic groin haematoma. Conclusions: Renal denervation is an effective treatment for resistant hypertension, although the effect observed was less than reported in previous studies. Objectives: We previously demonstrated associations between the urinary proteome profile and coronary artery disease (CAD). Here we evaluated the potential of urinary proteomics as a predictor of CAD in the 'Hypertension Associated Cardiovascular Disease' sub-study population of the ASCOT study. Methods: Thirty-seven cases with the primary endpoint CAD were selected and matched for sex and age within þ /À2 years to controls who had not reached a CAD endpoint during the study. Subjects with cardiovascular disease at baseline were not included. A spot urine sample collected at 1-1.5 years post randomisation was analysed using capillary electrophoresis (CE) coupled to Micro-TOF mass spectrometry (MS). The previously developed model for CAD and three unrelated models (chronic kidney disease, CKD; heart failure, HF; stroke) were assessed for their predictive values, and a classifier was calculated for each sample for each model.
High rates of non-adherence to antihypertensive treatment in patients from
Results:
Sixty urine samples (32 cases; 28 controls; 88% male, mean age 64±5 years) passed quality control. Classifiers were not different between cases and controls respectively for the CKD (À0.069±0.388 vs. À0.095±0.236, P ¼ 0.752), HF (0.282±0.663 vs. 0.114± 0.569, P ¼ 0.301) and stroke models (À0.114 ± 0.679 vs. À0.140 ± 0.528, P ¼ 0.868). There was a trend towards lower values for the CAD model (À0.432±0.326 vs. À0.587 ± 0.297, P ¼ 0.062), and the CAD model showed statistical significance on Kaplan-Meier survival analysis (P ¼ 0.021). Conclusions: Due to limited sample size this proofof-concept study cannot evaluate the predictive value of proteomics compared to other traditional risk factors. We have, however, shown that a CAD specific urinary proteome panel predicts CAD endpoints in a prospective study.
PA.3. Gender and regional differences in the treatment for hypertension: A pharmacoepidemiological analysis of the General Practice Research Database (GPRD) in the context of hypertension in atrial fibrillation (AF) patients Background: A recent study 1 utilising GPRD data showed that male AF patients in the UK are more likely to receive anticoagulation treatment than female patients. Recent work builds on this study to explore the treatment patterns of hypertension in AF patients. Objectives: The key objective of this research was to identify factors that influence the likelihood of AF patients with hypertension receiving hypertension treatment. As hypertension can be defined differently, this work also sought to identify the most appropriate classification of hypertension for use in future epidemiological studies. Methods: Logistic regression was applied to GPRD data to model the likelihood of hypertension treatment; a sensitivity analysis was applied to identify the most suitable definition of hypertension.
Results: After adjusting for other factors, overweight or diabetic individuals were more likely to receive treatment. Female patients were 30% more likely to be treated, while patients in the Midlands were about 30% less likely than those in Southern England to get treated. Finally the classification of hypertension as 'either diagnosis by GP or at least two blood pressure records in excess of 140/ 90 mm Hg in a twelve-month period' was identified as the most suitable for epidemiological studies. Conclusions: This study confirmed the influence of known risk factors of BMI and diabetes on the treatment of hypertension. Regional variations in hypertension treatment may exist. Contrary to the gender bias in anticoagulation of AF patients in favour of men, women were more likely to receive treatment for hypertension. Renal function and proteinuria: Estimated glomerular filtration rate (eGFR) was calculated in 70/74 and proteinuria quantified in 55/74 patients. The renal function was normal (490 ml/min/1.73 m 2 ) in 20% of patients. 24.3% of patients had eGFR o60 ml/ min/1.73 m 2 . Microalbuminuria was detected in 32.7% of patients and macroalbuminuria/proteinuria in a further 10.9%. Conclusion: We found a high prevalence of EOD in patients referred. Patients are predominantly referred to achieve target blood pressure, but the importance of detecting EOD and escalating treatment accordingly must not be lost.
PA.5. Pulse pressure is more strongly associated with incident coronary heart disease in South Asians than in Europeans. A cohort follow-up study Tillin T, Tuson C, Coady E, Chaturvedi N and Hughes AD Imperial College London, London, United Kingdom Background: South Asian populations across the world are at greater risk of coronary heart disease(CHD) compared with Europeans. Pulse pressure (PP), an indicator of arterial stiffness, is known to be predictive of cardiovascular events in Europeans, but it is not known whether it is equally predictive in South Asians. Methods: We used competing risks regression to study ethnicity-specific associations between baseline PP and incident CHD studied in a west London population-based cohort with 20 years of follow-up. At baseline (1988-91) participants, then aged 40-70, completed a health and lifestyle questionnaire and underwent fasting blood tests, anthropometry and blood pressure measurements. We excluded those with treated hypertension or known cardiovascular disease at baseline. CHD events were identified from primary care medical record review and death certificates. Non-invasive, cuff-based systems have recently become available for the assessment of central haemodynamic parameters. The aim of the current study was to compare measurements of cardiac output (CO) derived from one such device (Vicorder) with an established inert gas re-breathing method (Innocor). Comparisons were made at rest and in response to postural change (study 1) and mild exercise (study 2). Study 1 included 16 subjects, (mean age ± s.d. 35 ± 9 years). Haemodynamic indices (brachial blood pressure, CO, stroke volume (SV) and heart rate) were measured with both devices after 10 min each of supine and standing rest. Study 2 included 22 subjects (mean age 35 ± 8 years). Haemodynamic indices were measured at Abstracts rest and following 4 min of steady-state cycling on an upright cycle ergometer, at 20 rpm and 35 rpm, corresponding to 12 and 20 watts, respectively. Overall, the devices were significantly correlated for CO and SV; (r ¼ 0.43, P ¼ 0.001) and (r ¼ 0.32, P ¼ 0.001), respectively. There was a reasonable agreement between devices with a mean difference in CO of 0.6±1.4 l/minute (supine) and 1.0±1.2 l/ minute (standing). Similarly, in study 2, the mean difference was 0.4±1.2 l/minute (rest), À0.03±1.8 l/ minute and À1.1±3 l/minute cycling at 20 rpm and 35 rpm respectively (Figure 1 ). The Vicorder produces reasonable estimates of SV and CO compared to inert gas rebreathing, both at rest and in response to physiological challenges. Moreover, the Vicorder is simple-to-use and costeffective for comprehensive haemodynamic monitoring.
PA.7. Is it possible to transmit sounds through the arterial system as a means of measuring blood pressure? Background: We aim to study how vibrations propagate along the arterial system and whether a new non invasive method of measuring blood pressure in patients with arrhythmias is achievable. Method: 59 participants were included in the study, 18 had a normal BMI, 5 were underweight and 31 were considered moderately obese. Measurements with a doppler ultrasound were made at the brachial and radial arteries. A sensitive microphone was mounted within the acoustic pathway of a stethoscope. Artificial sounds were produced at the subclavian artery and detected by the three probes. Recordings were made on the left arm at three positions and two time intervals (cuff deflated and inflated.) The difference of the amplitude of sound waves during cuff deflation and inflation (VD1-VI1) and the difference of the frequency (FI1-FD1) was calculated.
Results: A significant attenuation of sound was caused by the restriction of blood flow through the brachial and radial artery. The microphone (VD1-VI1) was on average 66.45 mV (95% CI 23.9-52.9.) The (FI1-FD1) recorded by the microphone during the two time intervals was 5.03 Hz (95% Cl 7.6-2.45.) Indicating that frequency of sound waves rises with cuff pressure. Conclusion: The attenuation of artificial sounds during cuff inflation demonstrates that sound waves conduct through the arterial blood supply. This often coincides in time with the Korotkoff sounds. These observations suggest that the production of regular rhythmic vibrations may be used in addition to Korotkoff sounds as an audible criterion for recognising systolic pressure in patients with AF.
PB.1. Beat to beat variability in newly diagnosed hypertension
Agarwal M, Parkes MJ and Martin U
University of Birmingham, Birmingham, United Kingdom
Increased blood pressure (BP) variability is known to be associated with poor outcomes in patients with hypertension. Blood pressure variability is traditionally assessed using standard office and/or home BP measurements. Fluctuations in BP between each heart beat have not been studied but baroreflex sensitivity (BRS) has been shown to be reduced in hypertension, which might affect beat to beat variability. Seventeen newly diagnosed hypertensives (HT) (mean daytime ambulatory blood pressure monitoring (ABPM) 4135/85 mm Hg) and seventeen age-matched normotensive (NT) controls had beat to beat variability measured non-invasively using finger plethysmography (Finapres) while resting over a 1 h period. Data was analysed for the absolute sizes (mm Hg) of systolic beat-to-beat fluctuations. BRS was assessed using spontaneous baroreflex analysis techniques. The relationship of BP measured by Finapres to ABPM and clinic measurements was studied. The sizes of beat-to-beat fluctuations were similar in HT and NT ((mean± standard error) 3.6 ± 0.3 vs. 3.3 ± 0.3 mm Hg, P40.05). However, for each period of measurement there were a greater number of fluctuations in the HT group due to a significantly faster heart rate (72 ± 2 vs. 65 ± 2 beats/min). Baroreflex sensitivity was significantly reduced (Po0.001) in HT compared with NT in both expiration and inspiration. There were significant differences between mean Finapres and daytime ABPM measurements in some conditions. Beat-to-beat variability measured over 1 h does not appear to differ in unmedicated hypertensive patients compared to normotensive subjects despite reduced BRS. Figure) .
Used in routine practice, the Vicorder and SphygmoCor produced similar estimates of cSBP, although a greater disparity tended to be present in younger individuals. The ease of a cuffbased system for estimating cSBP is likely to be better suited to community-based screening programmes.
PB.5. Raised central pulse pressure in hypertension is predominately driven by changes in forward pressure wave Central pulse pressure (cPP), an important determinant of cardiovascular outcome, is determined by ventricular-vascular interaction. The extent to which pulsatile pressure waveform is determined by the forward and backward components is disputed. We decomposed cPP into components due to forward pressure waves (cPP FPW ) and backward pressure waves (cPP BPW ) generated by the ventricle and arterial tree respectively in hypertensive subjects (mean age±s.e. 47.4±3.0 years, BP: 158.5 ± 6.2/98.7 ± 3.2 mm Hg, n ¼ 20) and normotensive controls (mean age ± s.e. 52.2 ± 2.7 years, BP:108.7±2.7/ 71.8±1.7 mm Hg, n ¼ 20) and examined effects of dobutamine (to increase myocardial contractility) and norepinephrine (to increase peripheral arteriolar tone) on FPW and BPW in a subset of normotensive controls (n ¼ 10). Wave decomposition was performed on central pressure and flow waveforms obtained from carotid tonometry and aortic root Doppler flow velocity waveforms. cPP FPW was 50.4 ± 3.4 and 35.2 ± 1.8 mm Hg in hypertensives and controls respectively (Po0.001) and cPP BPW 8.9±1.7 and 1.6±0.4 mm Hg in hypertensives and controls respectively (Po0.002). After dobutamine (7.5 mg/min) cPP FPW increased from 36.4±3.7 to 57.3±3.0 mm Hg (Po0.001) but cPP BPW did not change significantly (1.5±1.0 and 2.6 ± 0.4 mm Hg at baseline and after dobutamine respectively, P ¼ NS). After norepinephrine (50 ng/min) cPP FPW did not change significantly (35.3 ± 1.6 and 39.0 ± 3.3 mm Hg at baseline and after norepinephrine respectively, P ¼ NS) but cPP BPW increased significantly from 2.0±1.0 to 5.6 ± 1.6 mm Hg (Po0.02). These data are consistent with cPP FPW and cPP BPW being determined by the left ventricle and peripheral arterial tree respectively. They suggest that in hypertension increased cPP results both from an increased ventricular and peripheral artery component but that the former dominates.
PC.1. Microvascular autoregulatory response to ischaemia and pulse pressure Adingupu DD, Elyas S, Casanova F, Gates PE, Shore AC and Strain WD Diabetes and Vascular Medicine, University of Exeter Medical School, Exeter, United Kingdom Introduction: Microvascular dysfunction is increasingly recognised in the transmission of higher systolic pressures to tissue beds, where it leads to hypertensive target organ damage. We have described three distinct cutaneous microvascular peak responses to an ischaemic stimulus using laser Doppler fluximetry which are associated with a clear gradation of cardiovascular risk. A 'normal peak' with a controlled graded rise to peak, 'non-dominant early peak (NDEP),' with an early peak within 2 s but which was lower than the subsequent 'normal' graded rise to peak, and 'dominant early peak (DEP)' within 2 s of cuff release, which declined rapidly and was then followed by a lesser 'normal' peak. Aims: To determine if there was association between pulse pressure and abnormal peak responses. Methods: Microvascular assessment post occlusive reactive hyperaemia (PORH) was performed on 126 participants with history of cardiovascular disease (CVD), 204 with type 2 diabetes and 111 controls, using laser Doppler DRT4 (Moor instruments, UK). Pulse pressure was calculated as systolic minus diastolic brachial blood pressure.
Results: Data was stratified by PORH peak response morphology, 148 classified as normal peak, 183 NDEP and 91 DEP responses. There was no difference in resting systolic and diastolic blood pressures and heart rate across peak response groups. There was a difference in pulse pressure between peak response group's normal, NDEP and DEP (mean±s.d. 54±11, 56±12, 59 ± 13 respectively, P ¼ 0.0042), with higher pulse pressure in DEP response group compared with normal peak response (P ¼ 0.004) and a trend for higher pulse pressure compared with NDEP (P ¼ 0.066). Conclusions: These data show that participants with more abnormal peak response morphology DEP have higher pulse pressure compared with more normal responses. The mechanisms underlying this association need further investigation.
spironolactone 25 mg od and irbesartan 300 mg od. 24 h urine metanephrines were abnormal, with metadrenaline 3866 nmol (Normal o2000) and normetadrenaline 52985 nmol (normal o4000). MRI scan showed a left para-aortic mass encasing the left renal vessels, and a second left para-aortic mass inferiorly. MIBG scan showed intense tracer uptake within the left para-aortic mass with a further focal area of intense uptake seen just inferior to mass. She underwent pre-operative a-and b-blockade, followed by adrenalectomy and splenectomy. She required 5 litres of fluid intraoperatively. Histopathology was consistent with a phaeochromocytoma and a paraganglioma. Six months post op, her daytime ABP was 147/93 on no antihypertensive medication. Her glucose intolerance had improved. Genetic studies are awaited. This case illustrates the need to exclude phaeochromocytoma prior to biopsy of a para-renal mass, and the need to re-investigate patients with a history of resistant hypertension to exclude a new or undetected secondary cause.
